The primary endpoint was the time from randomization to the first major cardiovascular event, such as death due to SS pathology, non-fatal myocardial infarction, non-fatal stroke. The efficacy and safety of Rybelsus® were evaluated in eight global randomized controlled clinical trials (CI) of phase IIIa. Of these, seven CI assessed the effectiveness of glycemic control…

All research referenced on this website complies with national and international regulations and guidelines for clinical trial information. The Peptide Report is dedicated to the timely disclosure of the design and results of interventional clinical studies, ensuring transparency and accessibility. • The Peptide Report research findings should not be interpreted as conclusive or definitive. The…